FDA Recalls & Court Actions: June 13, 1990
CLASS II -- LYPHOMED MULTI-VITAMIN CONCENTRATE In 5 ml single dose vials, 25 vials per shelf carton, an Rx injectable multivitamin (9 vitamins) for I.V. infusion. Lot numbers: 190428 EXP 5/90, 190811 EXP 9/90, 100022 EXP 1/91, 100128 EXP 2/91. (Also 190496 and 100042 distributed only in Canada). Manufacturer: Lyphomed, Inc., Melrose Park, Illinois. Recalled by: Lyphomed, Inc., Rosemont, Illinois, by letter April 20, 1990. Firm-initiated recall ongoing. Distribution: Nationwide, Puerto Rico, Hong Kong, Israel, Canada. 575,825 vials were distributed in the United States. Reason: Some units were found to have leakage around the metal closure which secures the metal stopper. CLASS II -- UDL BRAND AMOXICILLIN (AMOXICILLIN TRIHYDRATE) CAPSULES 500 mg, in unit dose cards of 10 in cartons containing 10 cards, an Rx semisynthetic pencillin. Lot number 21584 EX 8/1/91. Manufacturer: Biocraft Laboratories, Elmwood Park, New Jersey. Recalled by: Manufacturer, by letter May 14, 1990. Firm-initiated recall ongoing. Distribution: Distributed through one own-label distributor nationwide. 4,480 unit dose capsules were distributed. Reason: Mislabeling -- A package of 100 unit dose capsules of Amoxicillin 500 mg was found mislabeled as Oxacillin capsules 500 mg. The individual capsules were correctly labeled. CLASS II -- CORRECTION: Isosorbide Dinitrate Sublingual Tablets, USP, 5 mg, Lot number 9B173AR EXP 4/92 which appeared in the June 6, 1990 Enforcement Report ["The Pink Sheet" June 11, T&G-17]: The recall applies only to product distributed under the Qualitest label.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: